眼炎症治療の世界市場レポート 2025年

眼炎症治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.0％で125億8,000万米ドルに成長します。予測期間の成長は、生物学的製剤や標的治療に対する需要の高まり、早期診断と介入の重視、ヘルスケア支出の増加、眼科医療へのアクセス拡大、遠隔眼科ソリューションの採用拡大、新規治療に対する規制支援などに起因します。予測期間における主な動向としては、生物学的治療へのシフト、ドラッグデリバリーの進歩、個別化医療へのアプローチ、遠隔眼科医療との統合、安全性と有効性の重視、治療選択肢の拡大などが挙げられます。

高齢者の割合の増加が眼炎症治療市場の成長を刺激すると予想されます。加齢は、段階的な生理的低下と組織の完全性喪失を特徴とする自然なプロセスであり、ヘルスケアの向上、出生率の低下、平均寿命の延長などの要因により増加傾向にあります。高齢化社会が拡大するにつれ、加齢に伴う炎症関連症状から視力を管理・保護する眼炎症治療の需要が高まっています。例えば、世界保健機関（WHO）の報告書によると、60歳以上の人口は2020年の10億人から2022年には14億人へと大幅に増加し、2030年には世界の6人に1人が60歳以上になると予測されています。その結果、高齢化の進展が眼炎症治療市場を促進することになります。

眼炎症治療分野の有力企業は、自己乳化型ドラッグデリバリーシステム（SEDDS）技術などの先端技術を点眼薬に統合することに注力しています。この統合は、薬物の吸収を高め、治療効果を拡大し、患者の利便性を向上させることを目的としています。点眼薬におけるSEDDS技術は、治療薬のバイオアベイラビリティと眼への吸収性を高め、様々な眼疾患に対してより効果的な治療結果を約束します。例えば、ENTOD Pharmaceuticals社は2023年5月、炎症性ドライアイの患者をターゲットとしたCYCLOTEARS点眼薬を発売しました。CYCLOTEARSは、科学産業研究省（DSIR）の承認を受けたインドの科学者によって開発された、同社独自のSEDDS技術を搭載した世界初のドライアイ治療薬として際立っています。この技術の開発には、インド各地の著名な眼科研究機関との協力が役立っています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界眼炎症治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の眼炎症治療市場：成長率分析
• 世界の眼炎症治療市場の実績：規模と成長, 2019-2024
• 世界の眼炎症治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界眼炎症治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の眼炎症治療市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫抑制剤
• 抗ウイルス薬
• コルチコステロイド
• 抗生物質
• 鎮痛剤
• モノクローナル抗体
• 抗真菌剤
• 毛様体麻痺
• 世界の眼炎症治療市場：運用モード別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 注射剤
• オーラル
• トピック
• その他の動作モード
• 世界の眼炎症治療市場：疾患タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 前部ぶどう膜炎
• 中間ぶどう膜炎
• 上強膜炎/強膜炎
• 後部ぶどう膜炎
• ぶどう膜炎
• 世界の眼炎症治療市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 小売薬局
• オンライン薬局
• 病院薬局
• ドラッグストア
• 世界の眼炎症治療市場免疫抑制剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 全身免疫抑制剤（メトトレキサート、アザチオプリン）
• 局所免疫抑制剤（シクロスポリンA）
• 世界の眼炎症治療市場抗ウイルス薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口抗ウイルス薬（アシクロビル、バラシクロビル）
• 局所抗ウイルス薬（ガンシクロビル、イドクスウリジン）
• 世界の眼炎症治療市場コルチコステロイドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 局所コルチコステロイド（プレドニゾロン、デキサメタゾン）
• 全身性コルチコステロイド（経口プレドニゾン）
• 眼内ステロイド注射（トリアムシノロン）
• 世界の眼炎症治療市場抗生物質の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 局所抗生物質（トブラマイシン、ゲンタマイシン）
• 経口抗生物質（アジスロマイシン、シプロフロキサシン）
• 世界の眼炎症治療市場鎮痛剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非ステロイド性抗炎症薬（NSAID）
• オピオイド鎮痛剤（ヒドロコドン、オキシコドン）
• 世界の眼炎症治療市場、モノクローナル抗体のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗TNFαモノクローナル抗体（インフリキシマブ、アダリムマブ）
• 抗IL-6モノクローナル抗体（トシリズマブ）
• 世界の眼炎症治療市場抗真菌剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 局所抗真菌薬（ナタマイシン）
• 経口抗真菌薬（フルコナゾール、イトラコナゾール）
• 世界の眼炎症治療市場、毛様体麻痺のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アトロピン
• シクロペントレート
• トロピカミド

第7章 地域別・国別分析

• 世界の眼炎症治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の眼炎症治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 眼炎症治療市場：競合情勢
• 眼炎症治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• GlaxoSmithKline plc
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Regeneron Pharmaceuticals Inc.
• Mylan N.V.
• Bristol Myers Squibb Company
• Alcon Laboratories Inc.
• Bausch Health Companies Inc.
• Macleods Pharmaceuticals Ltd
• Intas Pharmaceuticals Ltd
• Cipla Inc.
• Santen Pharmaceutical Co. Ltd.
• Mallinckrodt Pharmaceuticals
• Akron Pharma Inc

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 眼炎症治療市場2029：新たな機会を提供する国
• 眼炎症治療市場2029：新たな機会を提供するセグメント
• 眼炎症治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Ocular inflammation treatment involves medical interventions aimed at reducing swelling and safeguarding the eyes from damage caused by inflammation, ensuring clear vision and eye health. Typically, treatment for ocular inflammation encompasses medication, eye drops, and occasionally additional therapies, tailored to the severity and underlying cause of the inflammation.

The primary types of ocular inflammation treatment include immunosuppressants, antivirals, corticosteroids, antibiotics, analgesics, monoclonal antibodies, antifungals, and cycloplegics. Immunosuppressants are medications designed to diminish the activity of the body's immune system, thereby aiding in controlling inflammation in the eyes. These treatment modalities are administered via injectables, orals, topicals, and other routes, targeting disease types such as anterior uveitis, intermediate uveitis, episcleritis/scleritis, posterior uveitis, and panuveitis. The distribution channels for these treatment products include retail pharmacies, online pharmacies, hospital pharmacies, and drug stores.

The ocular inflammation treatment market research report is one of a series of new reports from The Business Research Company that provides ocular inflammation treatment market statistics, including ocular inflammation treatment industry global market size, regional shares, competitors with a ocular inflammation treatment market share, detailed ocular inflammation treatment market segments, market trends and opportunities, and any further data you may need to thrive in the ocular inflammation treatment industry. This ocular inflammation treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ocular inflammation treatment market size has grown strongly in recent years. It will grow from $9.38 billion in 2024 to $9.97 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to advancements in ophthalmic research, an increased incidence of ocular inflammatory conditions, a growing aging population, the expansion of healthcare infrastructure, rising awareness about eye health, innovation in treatment modalities, and the and the development of novel therapeutics.

The ocular inflammation treatment market size is expected to see strong growth in the next few years. It will grow to $12.58 billion in 2029 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to rising demand for biologics and targeted therapies, emphasis on early diagnosis and intervention, increasing healthcare expenditure, expanding access to ophthalmic care, growing adoption of teleophthalmology solutions, regulatory support for novel treatments. Major trends in the forecast period include shift towards biologic therapies, advancements in drug delivery, personalized medicine approaches, teleophthalmology integration, regulatory emphasis on safety and efficacy, expansion of therapeutic options.

The increasing proportion of elderly individuals is anticipated to stimulate growth in the ocular inflammation treatment market. Aging, a natural process characterized by gradual physiological decline and tissue integrity loss, is on the rise due to factors such as improved healthcare, declining birth rates, and increased life expectancy. As the aging population expands, the demand for ocular inflammation treatment rises to manage and safeguard vision against age-related inflammation-related conditions. For instance, a report from the World Health Organization projected a significant increase in the demographic of individuals aged 60 and above, from 1 billion in 2020 to 1.4 billion by 2022, with estimates suggesting that one out of every six individuals globally will be aged 60 or older by 2030. Consequently, the aging population's growth will propel the ocular inflammation treatment market.

Prominent players in the ocular inflammation treatment sector are concentrating on integrating advanced technologies, such as self-emulsifying drug delivery system (SEDDS) technology, into eye drops. This integration aims to enhance drug absorption, extend therapeutic effects, and improve patient convenience. SEDDS technology in eye drops enhances bioavailability and ocular absorption of therapeutic agents, promising more effective treatment outcomes for various ocular conditions. For example, ENTOD Pharmaceuticals launched CYCLOTEARS eye drops in May 2023, targeting patients with inflammatory dry eye disease, a prevalent condition. CYCLOTEARS stands out as the world's first dry eye therapy to feature the company's proprietary SEDDS technology, developed by Indian scientists endorsed by the Department of Scientific and Industrial Research (DSIR). Collaborations with esteemed eye research institutes across India have been instrumental in the technology's development.

In June 2023, Bausch + Lomb acquired eye care products from Novartis AG for $1.75 billion, strategically strengthening its presence in the dry eye disease market segment. This acquisition, featuring Xiidra as a key asset, enhances Bausch + Lomb's ability to address the prevalent condition affecting millions globally. Novartis AG, a Swiss pharmaceutical corporation, specializes in producing drugs for ocular inflammation treatment.

Major companies operating in the ocular inflammation treatment market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, GlaxoSmithKline plc, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Bristol Myers Squibb Company, Alcon Laboratories Inc., Bausch Health Companies Inc., Macleods Pharmaceuticals Ltd, Intas Pharmaceuticals Ltd, Cipla Inc., Santen Pharmaceutical Co. Ltd., Mallinckrodt Pharmaceuticals, Akron Pharma Inc, Sun Pharmaceutical Industries Ltd., Alimera Sciences, Ocular Therapeutix Inc., EyePoint Pharmaceuticals Inc., Tarsier Pharma, Graybug Vision Inc., EyeGate, Oculis S.A.

North America was the largest region in the ocular inflammation treatment market in 2024. The regions covered in the ocular inflammation treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ocular inflammation treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ocular inflammation treatment market consists of revenues earned by entities by providing services such as diagnostic services, treatment administration services, patient support programs, telemedicine, and remote monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The ocular inflammation treatment market also includes sales of long-acting corticosteroid implants, contact lenses, compounded medications, and biodegradable inserts. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ocular Inflammation Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on ocular inflammation treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ocular inflammation treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The ocular inflammation treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Immunosuppressant; Antivirals; Corticosteroids; Antibiotics; Analgesics; Monoclonal Antibodies; Antifungal; Cycloplegic
• 2) By Mode of Operation: Injectables; Oral; Topical; Other Modes Of Operation
• 3) By Disease Type: Anterior Uveitis; Intermediate Uveitis; Episcleritis/Scleritis; Posterior Uveitis; Panuveitis
• 4) By Distribution Channel: Retail Pharmacies; Online Pharmacies; Hospital Pharmacies; Drug Stores
• Subsegments:
• 1) By Immunosuppressant: Systemic Immunosuppressants (Methotrexate, Azathioprine); Topical Immunosuppressants Cyclosporine A)
• 2) By Antivirals: Oral Antivirals ( Acyclovir, Valacyclovir); Topical Antivirals (Ganciclovir, Idoxuridine)
• 3) By Corticosteroids: Topical Corticosteroids ( Prednisolone, Dexamethasone); Systemic Corticosteroids (Oral Prednisone); Intraocular Steroid Injections (Triamcinolone)
• 4) By Antibiotics: Topical Antibiotics (Tobramycin, Gentamicin); Oral Antibiotics (Azithromycin, Ciprofloxacin)
• 5) By Analgesics: Non-Steroidal Anti-Inflammatory Drugs (Nsaids); Opioid Analgesics ( Hydrocodone, Oxycodone)
• 6) By Monoclonal Antibodies: Anti-Tnf Alpha Monoclonal Antibodies ( Infliximab, Adalimumab); Anti-Il-6 Monoclonal Antibodies ( Tocilizumab)
• 7) By Antifungal: Topical Antifungal ( Natamycin); Oral Antifungal ( Fluconazole, Itraconazole)
• 8) By Cycloplegic: Atropine; Cyclopentolate; Tropicamide
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Ocular Inflammation Treatment Market Characteristics

3. Ocular Inflammation Treatment Market Trends And Strategies

4. Ocular Inflammation Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Ocular Inflammation Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Ocular Inflammation Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Ocular Inflammation Treatment Market Growth Rate Analysis
• 5.4. Global Ocular Inflammation Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Ocular Inflammation Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Ocular Inflammation Treatment Total Addressable Market (TAM)

6. Ocular Inflammation Treatment Market Segmentation

• 6.1. Global Ocular Inflammation Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunosuppressant
• Antivirals
• Corticosteroids
• Antibiotics
• Analgesics
• Monoclonal Antibodies
• Antifungal
• Cycloplegic
• 6.2. Global Ocular Inflammation Treatment Market, Segmentation By Mode of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injectables
• Oral
• Topical
• Other Modes Of Operation
• 6.3. Global Ocular Inflammation Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anterior Uveitis
• Intermediate Uveitis
• Episcleritis/Scleritis
• Posterior Uveitis
• Panuveitis
• 6.4. Global Ocular Inflammation Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Retail Pharmacies
• Online Pharmacies
• Hospital Pharmacies
• Drug Stores
• 6.5. Global Ocular Inflammation Treatment Market, Sub-Segmentation Of Immunosuppressant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Systemic Immunosuppressants (Methotrexate, Azathioprine)
• Topical Immunosuppressants (Cyclosporine A)
• 6.6. Global Ocular Inflammation Treatment Market, Sub-Segmentation Of Antivirals, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Antivirals (Acyclovir, Valacyclovir)
• Topical Antivirals (Ganciclovir, Idoxuridine)
• 6.7. Global Ocular Inflammation Treatment Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Topical Corticosteroids (Prednisolone, Dexamethasone)
• Systemic Corticosteroids (Oral Prednisone)
• Intraocular Steroid Injections (Triamcinolone)
• 6.8. Global Ocular Inflammation Treatment Market, Sub-Segmentation Of Antibiotics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Topical Antibiotics (Tobramycin, Gentamicin)
• Oral Antibiotics (Azithromycin, Ciprofloxacin)
• 6.9. Global Ocular Inflammation Treatment Market, Sub-Segmentation Of Analgesics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• Opioid Analgesics (Hydrocodone, Oxycodone)
• 6.10. Global Ocular Inflammation Treatment Market, Sub-Segmentation Of Monoclonal Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anti-TNF Alpha Monoclonal Antibodies (Infliximab, Adalimumab)
• Anti-IL-6 Monoclonal Antibodies (Tocilizumab)
• 6.11. Global Ocular Inflammation Treatment Market, Sub-Segmentation Of Antifungal, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Topical Antifungal (Natamycin)
• Oral Antifungal (Fluconazole, Itraconazole)
• 6.12. Global Ocular Inflammation Treatment Market, Sub-Segmentation Of Cycloplegic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Atropine
• Cyclopentolate
• Tropicamide

7. Ocular Inflammation Treatment Market Regional And Country Analysis

• 7.1. Global Ocular Inflammation Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Ocular Inflammation Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Ocular Inflammation Treatment Market

• 8.1. Asia-Pacific Ocular Inflammation Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Ocular Inflammation Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Ocular Inflammation Treatment Market, Segmentation By Mode of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Ocular Inflammation Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Ocular Inflammation Treatment Market

• 9.1. China Ocular Inflammation Treatment Market Overview
• 9.2. China Ocular Inflammation Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Ocular Inflammation Treatment Market, Segmentation By Mode of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Ocular Inflammation Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Ocular Inflammation Treatment Market

• 10.1. India Ocular Inflammation Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Ocular Inflammation Treatment Market, Segmentation By Mode of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Ocular Inflammation Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Ocular Inflammation Treatment Market

• 11.1. Japan Ocular Inflammation Treatment Market Overview
• 11.2. Japan Ocular Inflammation Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Ocular Inflammation Treatment Market, Segmentation By Mode of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Ocular Inflammation Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Ocular Inflammation Treatment Market

• 12.1. Australia Ocular Inflammation Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Ocular Inflammation Treatment Market, Segmentation By Mode of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Ocular Inflammation Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Ocular Inflammation Treatment Market

• 13.1. Indonesia Ocular Inflammation Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Ocular Inflammation Treatment Market, Segmentation By Mode of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Ocular Inflammation Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Ocular Inflammation Treatment Market

• 14.1. South Korea Ocular Inflammation Treatment Market Overview
• 14.2. South Korea Ocular Inflammation Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Ocular Inflammation Treatment Market, Segmentation By Mode of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Ocular Inflammation Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Ocular Inflammation Treatment Market

• 15.1. Western Europe Ocular Inflammation Treatment Market Overview
• 15.2. Western Europe Ocular Inflammation Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Ocular Inflammation Treatment Market, Segmentation By Mode of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Ocular Inflammation Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Ocular Inflammation Treatment Market

• 16.1. UK Ocular Inflammation Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Ocular Inflammation Treatment Market, Segmentation By Mode of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Ocular Inflammation Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Ocular Inflammation Treatment Market

• 17.1. Germany Ocular Inflammation Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Ocular Inflammation Treatment Market, Segmentation By Mode of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Ocular Inflammation Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Ocular Inflammation Treatment Market

• 18.1. France Ocular Inflammation Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Ocular Inflammation Treatment Market, Segmentation By Mode of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Ocular Inflammation Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Ocular Inflammation Treatment Market

• 19.1. Italy Ocular Inflammation Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Ocular Inflammation Treatment Market, Segmentation By Mode of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Ocular Inflammation Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Ocular Inflammation Treatment Market

• 20.1. Spain Ocular Inflammation Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Ocular Inflammation Treatment Market, Segmentation By Mode of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Ocular Inflammation Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Ocular Inflammation Treatment Market

• 21.1. Eastern Europe Ocular Inflammation Treatment Market Overview
• 21.2. Eastern Europe Ocular Inflammation Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Ocular Inflammation Treatment Market, Segmentation By Mode of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Ocular Inflammation Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Ocular Inflammation Treatment Market

• 22.1. Russia Ocular Inflammation Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Ocular Inflammation Treatment Market, Segmentation By Mode of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Ocular Inflammation Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Ocular Inflammation Treatment Market

• 23.1. North America Ocular Inflammation Treatment Market Overview
• 23.2. North America Ocular Inflammation Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Ocular Inflammation Treatment Market, Segmentation By Mode of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Ocular Inflammation Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Ocular Inflammation Treatment Market

• 24.1. USA Ocular Inflammation Treatment Market Overview
• 24.2. USA Ocular Inflammation Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Ocular Inflammation Treatment Market, Segmentation By Mode of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Ocular Inflammation Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Ocular Inflammation Treatment Market

• 25.1. Canada Ocular Inflammation Treatment Market Overview
• 25.2. Canada Ocular Inflammation Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Ocular Inflammation Treatment Market, Segmentation By Mode of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Ocular Inflammation Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Ocular Inflammation Treatment Market

• 26.1. South America Ocular Inflammation Treatment Market Overview
• 26.2. South America Ocular Inflammation Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Ocular Inflammation Treatment Market, Segmentation By Mode of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Ocular Inflammation Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Ocular Inflammation Treatment Market

• 27.1. Brazil Ocular Inflammation Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Ocular Inflammation Treatment Market, Segmentation By Mode of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Ocular Inflammation Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Ocular Inflammation Treatment Market

• 28.1. Middle East Ocular Inflammation Treatment Market Overview
• 28.2. Middle East Ocular Inflammation Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Ocular Inflammation Treatment Market, Segmentation By Mode of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Ocular Inflammation Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Ocular Inflammation Treatment Market

• 29.1. Africa Ocular Inflammation Treatment Market Overview
• 29.2. Africa Ocular Inflammation Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Ocular Inflammation Treatment Market, Segmentation By Mode of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Ocular Inflammation Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Ocular Inflammation Treatment Market Competitive Landscape And Company Profiles

• 30.1. Ocular Inflammation Treatment Market Competitive Landscape
• 30.2. Ocular Inflammation Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Ocular Inflammation Treatment Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. GlaxoSmithKline plc
• 31.3. Amgen Inc.
• 31.4. Teva Pharmaceutical Industries Ltd.
• 31.5. Regeneron Pharmaceuticals Inc.
• 31.6. Mylan N.V.
• 31.7. Bristol Myers Squibb Company
• 31.8. Alcon Laboratories Inc.
• 31.9. Bausch Health Companies Inc.
• 31.10. Macleods Pharmaceuticals Ltd
• 31.11. Intas Pharmaceuticals Ltd
• 31.12. Cipla Inc.
• 31.13. Santen Pharmaceutical Co. Ltd.
• 31.14. Mallinckrodt Pharmaceuticals
• 31.15. Akron Pharma Inc

32. Global Ocular Inflammation Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Ocular Inflammation Treatment Market

34. Recent Developments In The Ocular Inflammation Treatment Market

35. Ocular Inflammation Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Ocular Inflammation Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Ocular Inflammation Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Ocular Inflammation Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer